Turtle Cameron 4
4 · Spyre Therapeutics, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Turtle Cameron
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-02$41.73/sh−5,900$246,207→ 651,640 total - Sale
Common Stock
[F1][F4][F3]2026-03-02$42.49/sh−9,100$386,659→ 642,540 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact|2026-03-03